Switch theme
Sign up to access all valuation multiples
Tibet Cheezheng Tibetan Medicine Co Ltd is Tibetan medicine manufacturer. It is mainly engaged in the research, development, production, and sales of Tibetan medicines. The company's products include medicines such as emplastrum, ointments, granules, pills, and powders.
1997
1.2K+
Last FY Revenue $324M
Last FY EBITDA $117M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Cheezheng Tibetan Medicine achieved revenue of $324M and an EBITDA of $117M.
Cheezheng Tibetan Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cheezheng Tibetan Medicine valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $324M | XXX | XXX | XXX |
| Gross Profit | XXX | $266M | XXX | XXX | XXX |
| Gross Margin | XXX | 82% | XXX | XXX | XXX |
| EBITDA | XXX | $117M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 36% | XXX | XXX | XXX |
| EBIT | XXX | $84.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | 26% | XXX | XXX | XXX |
| Net Profit | XXX | $80.8M | XXX | XXX | XXX |
| Net Margin | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | $197M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cheezheng Tibetan Medicine's stock price is CNY 24 (or $3).
Cheezheng Tibetan Medicine has current market cap of CNY 12.9B (or $1.8B), and EV of CNY 11.5B (or $1.6B).
See Cheezheng Tibetan Medicine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cheezheng Tibetan Medicine has market cap of $1.8B and EV of $1.6B.
Cheezheng Tibetan Medicine's trades at 4.9x EV/Revenue multiple, and 13.7x EV/EBITDA.
Equity research analysts estimate Cheezheng Tibetan Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cheezheng Tibetan Medicine's P/E ratio is not available.
See valuation multiples for Cheezheng Tibetan Medicine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 18.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 22.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 57.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCheezheng Tibetan Medicine's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Cheezheng Tibetan Medicine's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cheezheng Tibetan Medicine's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cheezheng Tibetan Medicine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cheezheng Tibetan Medicine acquired XXX companies to date.
Last acquisition by Cheezheng Tibetan Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Cheezheng Tibetan Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cheezheng Tibetan Medicine founded? | Cheezheng Tibetan Medicine was founded in 1997. |
| Where is Cheezheng Tibetan Medicine headquartered? | Cheezheng Tibetan Medicine is headquartered in China. |
| How many employees does Cheezheng Tibetan Medicine have? | As of today, Cheezheng Tibetan Medicine has 1.2K+ employees. |
| Is Cheezheng Tibetan Medicine publicy listed? | Yes, Cheezheng Tibetan Medicine is a public company listed on SHE. |
| What is the stock symbol of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine trades under 002287 ticker. |
| When did Cheezheng Tibetan Medicine go public? | Cheezheng Tibetan Medicine went public in 2009. |
| Who are competitors of Cheezheng Tibetan Medicine? | Similar companies to Cheezheng Tibetan Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine's current market cap is $1.8B |
| Is Cheezheng Tibetan Medicine profitable? | Yes, Cheezheng Tibetan Medicine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
